Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis
Abstract
Aim: A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12–16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab. Patients & methods: Trials were identified by systematic review. Separate networks were developed for the full-study populations, biologic-naive patients and biologic-experienced patients. Results: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. Conclusion: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive network meta-analysis demonstrated superiority to placebo.
Supplementary Material
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract. Res. Clin. Rheumatol. 28(5), 663–672 (2014).
• Provides an introduction to spondyloarthritis.
2.
Smolen JS, Schols M, Braun J et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann. Rheum. Dis. 77(1), 3–17 (2018).
•• Defines treatment aims for spondyloarthritis, based on published literature and consultation with clinical experts.
3.
Coates LC, Murphy R, Helliwell PS. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br. J. Dermatol. 174(6), 1174–1178 (2016).
4.
Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75(3), 499–510 (2016).
5.
Tintle SJ, Gottlieb AB. Psoriatic arthritis for the dermatologist. Dermatol. Clin. 33(1), 127–148 (2015).
6.
Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 141(2), 133–142 (2014).
7.
Konya C, Paz Z, Apostolidis SA, Tsokos GC. Update on the role of interleukin 17 in rheumatologic autoimmune diseases. Cytokine 75(2), 207–215 (2015).
8.
Smith JA, Colbert RA. Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 66(2), 231–241 (2014).
9.
Blauvelt A, Reich K, Tsai TF et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J. Am. Acad. Dermatol. 76(1), 60–69, e69 (2017).
10.
Gottlieb AB, Langley RG, Philipp S et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, Phase III trials. J. Drugs Dermatol. 14(8), 821–833 (2015).
11.
Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362(2), 118–128 (2010).
12.
ClinicalTrials.gov. NCT02745080. Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritis (EXCEED 1). https://clinicaltrials.gov/ct2/show/NCT02745080 (Accessed 29 June 2018).
13.
ClinicalTrials.gov. A study of ixekizumab (LY2439821) versus adalimumab in participants with psoriatic arthritis (SPIRIT-H2H). https://clinicaltrials.gov/ct2/show/NCT03151551 (Accessed 29 June 2018).
14.
Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. Med. Decis. Making 33(5), 597–606 (2013).
• Provides an overarching introduction to evidence synthesis methods for decision making.
15.
Greco T, Biondi-Zoccai G, Saleh O et al. The attractiveness of network meta-analysis: a comprehensive systematic and narrative review. Heart Lung Vessel 7(2), 133–142 (2015).
16.
Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis. Curr. Med. Res. Opin. 32(4), 721–729 (2016).
17.
Cawson MR, Mitchell SA, Knight C et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet. Disord. 15, 26 (2014).
18.
Strand V, Husni ME, Reichmann W et al. Network meta-analysis of tumor necrosis factor, interleukins, and phosphodiesterase-4 inhibitor in the treatment of psoriatic arthritis. Presented at: The 2015 ACR/ARHP Annual Meeting, CA, USA, 6–11 November 2015.
19.
Ungprasert P, Thongprayoon C, Davis JM 3rd. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis. Semin. Arthritis Rheum. 45(4), 428–438 (2016).
20.
Van Sanden S, Diels J, Van Laer J, Hemels M. Network meta-analysis with baseline risk adjustment to assess the relative efficacy of ustekinumab in adult patients with active psoriatic arthritis. Value Health 17(7), A373 (2014).
21.
Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607–617 (2013).
•• Sets out established standards for the modeling methodology used in our study.
22.
Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417–428 (2011).
• Discusses good research practices for indirect treatment comparisons.
23.
Mease PJ, Van der Heijde D, Ritchlin CT et al. A randomized, double-blind, active- and placebo-controlled Phase III study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis. Arthritis Rheumatol. 67(Suppl. 10), (2015).
24.
Mease PJ, van der Heijde D, Ritchlin CT et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the Phase III trial SPIRIT-P1. Ann. Rheum. Dis. (2016) (Epub ahead of print).
25.
Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(10), 3279–3289 (2005).
26.
Mease PJ, McInnes IB, Kirkham B et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373(14), 1329–1339 (2015).
27.
McInnes IB, Mease PJ, Kirkham B et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 386(9999), 1137–1146 (2015).
•• This is the primary trial publication for the secukinumab data used in our analysis.
28.
Genovese MC, Mease PJ, Thomson GT et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J. Rheumatol. 34(5), 1040–1050 (2007).
29.
Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4), 976–986 (2009).
30.
Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52(4), 1227–1236 (2005).
31.
Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64(8), 1150–1157 (2005).
32.
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227), 385–390 (2000).
33.
Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7), 2264–2272 (2004).
34.
Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Treatment of psoriatic arthritis in a Phase III randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73(6), 1020–1026 (2014).
35.
Cutolo M, Myerson GE, Fleischmann RM et al. A Phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J. Rheumatol. 43(9), 1724–1734 (2016).
36.
Cutolo M, Myerson GE, Fleischmann RM et al. Long-term (52-week) results of a Phase III, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis Rheum. 65(Suppl. 10), 815 (2013).
37.
Birbara C, Blanco FJ, Crowley JJ, Hu C, Stevens R, Edwards CJ. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis including current skin involvement: results of a Phase III, randomized, controlled trial. Ann. Rheum. Dis. 72(Suppl. 3), A85–A86 (2013).
38.
Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340, c147 (2010).
39.
McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the Phase III, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894), 780–789 (2013).
40.
Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the Phase III, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73(6), 990–999 (2014).
41.
Mease PJ, Fleischmann R, Deodhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase III double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 73(1), 48–55 (2014).
42.
Schett G, Wollenhaupt J, Papp K et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 64(10), 3156–3167 (2012).
43.
Dias S, Sutton AJ, Welton NJ, Ades AE. National Institute for Health and Care Excellence Decision Support Unit technical support document no. 3. Heterogeneity: subgroups, meta-regression, bias and bias-adjustment (2012). www.nicedsu.org.uk.
44.
European Medicines Agency (EMA). Assessment report: Otezla. International non-proprietary name: apremilast (2014). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003746/WC500182629.pdf.
45.
European Medicines Agency (EMA). EPAR summary for the public. Stelara (ustekinumab) (2016). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000958/WC500058509.pdf.
46.
Orbai AM, Ogdie A. Patient-reported outcomes in psoriatic arthritis. Rheum. Dis. Clin. North Am. 42(2), 265–283 (2016).
47.
National Institute for Health and Care Excellence (NICE). Multiple technology appraisal. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs [ID579]. Committee papers (2016). www.nice.org.uk/guidance/GID-TAG521/documents/committee-papers.
48.
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Report by the Decision Support Unit (2016). http://research-information.bristol.ac.uk/files/94868463/Population_adjustment_TSD_FINAL.pdf.
49.
Nash P, McInnes IB, Mease PJ et al. Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison. Rheumatol. Ther. 5(1), 99–122 (2018).
Information & Authors
Information
Published In
Copyright
© 2018 Steffen M Jugl.
History
Received: 19 July 2018
Accepted: 3 September 2018
Published online: 19 September 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0075
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Matthew L. Stoll, Peter A. Nigrovic, Psoriatic Juvenile Idiopathic Arthritis, Textbook of Pediatric Rheumatology, 10.1016/B978-0-443-11980-4.00021-0, (286-297), (2027).
- Muhammad Saad Khan, Saim Mahmood Khan, Rabia Farooq, Aliza Arif, Abiha Murshid, Muhammad Abdullah, Ayesha Ismail, Jawairya Muhammad Hussain, Shayan Rahim, Syeda Neha Ahmed, Surraiya Riaz Mahmood Khan, Efficacy, Safety, and Tolerability of Secukinumab in Psoriatic Arthritis: A Systematic Review and Meta-Analysis, Annals of Pharmacotherapy, 10.1177/10600280261442115, (2026).
- Maria E. Ramos-Nino, Operationalizing Chronic Inflammation: An Endotype-to-Care Framework for Precision and Equity, Clinics and Practice, 10.3390/clinpract15120233, 15, 12, (233), (2025).
- Epipode Ntawuyamara, Baoqing Deng, Yanhua Liang, Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study, Scientific Reports, 10.1038/s41598-025-99075-9, 15, 1, (2025).
- Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John D Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie Crofford, Ronald F van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Tom WJ Huizinga, Ellen M Gravallese, Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023, Annals of the Rheumatic Diseases, 10.1136/ard-2023-224916, 83, 4, (409-416), (2024).
- Thais Montezuma, Livia Fernandes Probst, Matheus Oliveira Almeida, Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis, Advances in Rheumatology, 10.1186/s42358-024-00361-3, 64, 1, (2024).
- Peter Nash, Jan P Dutz, Steve Peterson, Barkha P Patel, Kiefer Eaton, May Shawi, Federico Zazzetti, James Cheng-Chung Wei, Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes, BMJ Open, 10.1136/bmjopen-2022-062306, 13, 11, (e062306), (2023).
- Bente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C Nordström, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A Provan, Brigitte Michelsen, Eirik Klami Kristianslund, Lene Dreyer, Thorvardur Jon Love, Ulf Lindström, Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries, Annals of the Rheumatic Diseases, 10.1136/ard-2022-223650, 82, 6, (820-828), (2023).
- Piyameth Dilokthornsakul, Ratree Sawangjit, Manathip Osiri, Praveena Chiowchanwisawakit, Worawit Louthrenoo, Unchalee Permsuwan, Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand, Value in Health Regional Issues, 10.1016/j.vhri.2022.10.005, 34, (40-47), (2023).
- Iain B McInnes, Laura M Sawyer, Kristen Markus, Corinne LeReun, Celia Sabry-Grant, Philip S Helliwell, Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes, RMD Open, 10.1136/rmdopen-2021-002074, 8, 1, (e002074), (2022).